Leerink Partners analysts see no near-term material changes to U.S. onshoring narrative, given Trump’s executive order late last week on pharmaceutical imports.
The Toa Baja facility is designed to the same standards as the company’s existing Taichung, Taiwan manufacturing site and is to begin operations in 2027.
